Price to earnings forward of Penumbra, Inc. – DUS:0P8
This article provides financial data for Penumbra, Inc. (DUS:0P8) on the Dusseldorf Stock Exchange, specifically focusing on its forward Price to Earnings ratio. It presents an overview of the company's financials without detailed numbers, noting the market was closed at the time of data retrieval.
PEN - Penumbra Inc Volatility & Greeks
This article provides a detailed financial overview of Penumbra Inc (PEN), including its latest stock performance, key financial metrics, volatility data, and analyst recommendations. It covers various fundamental and technical indicators, insider and institutional ownership, and historical performance over different periods.
Penumbra Receives CE Mark for Reperfusion Catheters
Penumbra Inc. has received the CE Mark for its Red 72 Silver Label and Red 72 Silver Label with SENDit Technology reperfusion catheters, designed for acute ischemic stroke. These devices offer significant engineering updates for enhanced trackability and ease of navigation, building on Penumbra's two decades of experience in neurovascular interventions. The Red 72 Silver Label was previously released in the US in April 2025 and has been shown to improve treatment for patients with large vessel occlusion.
Penumbra secures European CE mark for Red 72 Silver Label technologies
Penumbra has received CE mark approval for its Red 72 Silver Label and Red 72 Silver Label with Sendit technology products in Europe. These reperfusion catheters, already available in the USA, offer significant updates for treating large vessel occlusion in acute ischemic stroke patients. The company highlights the devices' enhanced trackability and ease of navigation for faster and safer recanalization.
Penumbra, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh
This page provides an overview of financial actuals and estimates for Penumbra, Inc. (BMFBOVESPA:P2NB34), specifically for its Unsponsored Brazilian Depositary Receipt. Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends over time.
PEN Forecast — Price Target — Prediction for 2027
This article provides a forecast for Penumbra, Inc. (PEN) stock, including analyst price targets, earnings estimates, and revenue projections. Analysts have provided 1-year price targets for PEN, with a maximum estimate of 6,593.79 MXN and a minimum estimate of 5,906.21 MXN. The company is expected to release its next earnings report on August 4, 2026, with reported earnings for the last quarter at 14.71 MXN per share and revenue at 6.72 billion MXN.
Price to sales forward of Penumbra, Inc. – HAM:0P8
This page from TradingView focuses on the "Price to sales forward" financial metric for Penumbra, Inc. (HAM:0P8) on the Hamburg Stock Exchange. Although specific financial figures are not detailed, the page indicates that it provides human-made data and is part of TradingView's comprehensive financial and market analysis tools.
Price to earnings forward of Penumbra, Inc. – HAM:0P8
This article provides financial information for Penumbra, Inc. (HAM:0P8) on the Hamburg Stock Exchange, specifically focusing on its Price to Earnings Forward. The content presents an overview of the company's financials and includes metadata from TradingView.
Price to sales forward of Penumbra, Inc. – NYSE:PEN
This article focuses on the "Price to sales forward" metric for Penumbra, Inc. (NYSE: PEN). It presents the company's financial data as provided by TradingView, detailing its market information and stock exchange listing. The content mainly consists of navigational links and copyright information, with limited specific financial data presented in the body.
Penumbra, Inc. 8-K SEC Filing: Key Details, Business Address, NYSE Listing & Shareholder Vote Results
Penumbra, Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026, where shareholders voted on the election of directors, ratification of the independent auditor, and an advisory vote on executive compensation. All proposals passed by significant margins, indicating strong shareholder confidence in the company's leadership and strategic direction. The results suggest stability in governance and are unlikely to cause immediate major share price movements.
Penumbra: Portfolio Expands With Approval To Treat Stroke; Acquisition by Boston on Track
Penumbra recently received US Food and Drug Administration approval and the CE Mark for its Thunderbolt computer-assisted vacuum aspiration system for ischemic stroke, expanding its portfolio. Concurrently, Boston Scientific is in the process of acquiring Penumbra. This development highlights Penumbra's continued growth in medical device innovation for stroke treatment.
Penumbra (PEN) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary
Penumbra presented at the Canaccord Genuity 44th Annual Growth Conference, focusing on its thrombectomy and embolization/access business units. The company highlighted its CAVT technology, including Lightning Flash 2.0 and Lightning Bolt 7, and the upcoming Thunderbolt for stroke. Penumbra also discussed its $200 million share buyback program and optimistic financial growth prospects for 2025 and 2026, driven by product performance and market penetration in thrombectomy.
Penumbra shareholders elect directors and approve executive pay at annual meeting
Penumbra Inc. shareholders met to elect three Class II directors to serve until the 2027 annual meeting, ratify PricewaterhouseCoopers LLP as the independent public accounting firm, and approve executive compensation. The medical device company also recently received CE Mark approval for its THUNDERBOLT device in Europe and FDA clearance in the U.S., and shareholders approved a merger with Boston Scientific Corporation. Additionally, results from the STORM-PE trial indicated improved patient outcomes using Penumbra’s technology for pulmonary embolism.
Form 8K Penumbra Inc For: 22 June By Investing.com
This article announces that Penumbra Inc. filed a Form 8K for June 22. The article is very brief, serving mainly as a headline with no additional details about the filing's content. It also includes stock market data and other news.
Penumbra Expands Portfolio With Approval To Treat Stroke; Acquisition by Boston on Track
Penumbra, a company specializing in endovascular systems for blood clots and aneurysms, has received approval to treat stroke. This development comes as the company is on track to be acquired by Boston Scientific by the end of 2026. Penumbra has built a growing presence in the therapeutic markets over the last 20 years, competing with major players like Stryker, Medtronic, and Terumo.
(PEN) Price Dynamics and Execution-Aware Positioning
This article provides an AI-driven analysis for Penumbra Inc. (NYSE: PEN), indicating a neutral near and mid-term outlook with a moderating long-term positive bias and elevated downside risk. It details various trading strategies—position, momentum breakout, and risk hedging—along with multi-timeframe signal analysis for support and resistance levels. The report emphasizes the current neutral sentiment and lack of clear price positioning signals.
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
Penumbra recently received CE Mark approval in Europe for its THUNDERBOLT technology, a computer-assisted vacuum thrombectomy (CAVT) device for acute ischemic stroke, following FDA approval in the U.S. This expansion is expected to boost Penumbra's international revenues, which already contribute significantly to its total revenue. The article suggests positive market sentiment for PEN stock due to this development and highlights the importance of THUNDERBOLT in advancing stroke care, a leading cause of death worldwide.
Penumbra wins CE mark for Thunderbolt clot removal tech
Penumbra has secured a CE mark for its Thunderbolt computer-assisted vacuum thrombectomy device, allowing its launch in Europe for stroke patients. This European certification follows FDA clearance and positions Penumbra for global expansion, which could be significantly bolstered by Boston Scientific's worldwide infrastructure after its impending acquisition of Penumbra. Analysts anticipate Thunderbolt could generate substantial incremental revenue, leveraging Boston Scientific's capabilities to increase international sales.
Penumbra Inc (PEN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Penumbra Inc (PEN), noting its current valuation score of 7.10, which ranks 176 out of 204 in its industry. The company's current P/E ratio is 72.21, significantly below its recent high but above its recent low. The article indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by Penumbra Inc.
Penumbra (PEN) Proxy filing Summary
The proxy filing details a proposed merger where Penumbra will be acquired by Boston Scientific in a cash and stock transaction valued at $374.00 per share. Penumbra shareholders can choose between cash or Boston Scientific shares, subject to proration, and the Penumbra board unanimously recommends shareholders vote in favor of the merger. The special meeting for approval is set for May 6, 2026, with the merger expected to close in 2026 pending regulatory approvals.
Penumbra Inc (PEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Penumbra Inc (PEN), focusing on its business segments and regional contributions. The company's revenue is primarily driven by Thrombectomy and Embolization and Access segments, with the majority of sales originating from the United States. The data is updated as of April 6, covering fiscal year 2025 and 2024.
CE Mark Granted to Penumbra's CAVT Platform
Penumbra, Inc. has received CE Mark approval in Europe for its Thunderbolt computer-assisted vacuum thrombectomy (CAVT) platform, which is designed to treat acute ischemic stroke. This follows recent U.S. FDA clearance and aims to enable more rapid and complete clot removal for stroke patients globally. The technology, powered by the Penumbra Engine, introduces modulated aspiration to detect, fatigue, and ingest clots more effectively.
Penumbra expands CAVT for stroke into Europe with Thunderbolt CE mark
Penumbra has received CE mark approval in Europe for its Thunderbolt device, expanding its computer-assisted vacuum thrombectomy (CAVT) technology for acute ischaemic stroke treatment. This follows recent US FDA clearance, making Thunderbolt the only CAVT device available in both regions for stroke. The company states that the technology, powered by the Penumbra Engine, aims to improve stroke management through modulated aspiration, leading to better patient outcomes and potentially shorter procedure times.
Penumbra earns CE mark for Thunderbolt thrombectomy system
Penumbra has received CE mark approval for its Thunderbolt thrombectomy system, a computer-assisted vacuum thrombectomy (CAVT) technology for acute ischemic stroke. This European approval follows a recent FDA clearance, making Thunderbolt the only CAVT device available in both the U.S. and Europe for stroke treatment. The system aims to improve patient care by detecting, fatiguing, and ingesting clots, potentially shortening procedure times.
Penumbra (PEN) Achieves CE Mark for Thunderbolt Technology
Penumbra Inc. (PEN) has obtained the CE Mark in Europe for its Thunderbolt system, a computer-assisted vacuum thrombectomy technology used for treating acute ischemic stroke. This follows a recent U.S. FDA clearance, positioning the company for broader adoption of its innovative medical solutions. Despite a high P/E ratio suggesting investor growth expectations, the company holds a strong GF Score™ of 89/100 and solid financial strength.
Penumbra secures CE Mark for stroke treatment device in Europe
Penumbra, Inc. has obtained CE Mark approval in Europe for its THUNDERBOLT device, a computer-assisted vacuum thrombectomy system designed for acute ischemic stroke. This follows recent U.S. FDA clearance and marks a significant expansion into the European market for the medical device company. Despite strong revenue growth, InvestingPro analysis suggests the stock is currently overvalued.
Penumbra Inc Expands Cavt For Stroke To Europe With CE Mark For Thunderbolt
Penumbra Inc. has received CE Mark approval for its Thunderbolt technology, allowing the company to expand its Peripheral AngioJet revascularization system (CAVT) for stroke treatment into Europe. This expansion signifies a significant step for Penumbra in reaching a broader market with its medical devices.
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
Penumbra, Inc. has secured CE Mark in Europe for its THUNDERBOLT™ Computer Assisted Vacuum Thrombectomy (CAVT™) technology, designed for acute ischemic stroke. This follows a recent U.S. FDA clearance, positioning THUNDERBOLT as the first CAVT device for stroke treatment in both Europe and the U.S. The technology introduces modulated aspiration to enable more rapid and complete clot removal, aiming to significantly improve patient outcomes and streamline care.
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
Penumbra, Inc. has secured CE Mark in Europe for its THUNDERBOLT™ Computer Assisted Vacuum Thrombectomy (CAVT™) technology, designed for acute ischemic stroke treatment. This follows recent U.S. FDA clearance, positioning THUNDERBOLT as the first CAVT device for stroke treatment in Europe, aiming to improve clot removal, shorten procedure times, and enhance patient outcomes. The company emphasizes its commitment to transforming treatment for life-threatening clots globally.
Boston Scientific Eyes Neurovascular Growth With Penumbra Thunderbolt Clearance
Boston Scientific (NYSE:BSX) is poised to expand its neurovascular portfolio with the upcoming acquisition of Penumbra, which recently received FDA clearance for its Thunderbolt stroke thrombectomy device. This clearance adds a significant asset to Boston Scientific's planned offerings for stroke intervention. Key considerations for investors include the adoption rate of Thunderbolt, the integration of Penumbra's technology, and how this will contribute to Boston Scientific's overall neurovascular strategy.
Penumbra CAVT Platform Receives FDA Clearance
Penumbra, Inc. has received FDA clearance for its Thunderbolt platform, expanding its computer-assisted vacuum thrombectomy (CAVT) technology for acute ischemic stroke treatment. The Thunderbolt platform aims to deliver modulated aspiration for faster and more complete clot removal, thereby minimizing catheter manipulation and improving patient outcomes. This advancement positions Penumbra as the sole provider of CAVT technology for both vascular and neurovascular conditions in the U.S., marking a significant step in stroke management.
FDA OKs Penumbra’s Thunderbolt Computer-Assisted Vacuum Thrombectomy for Stroke
Penumbra has received FDA clearance for Thunderbolt, a new computer-assisted vacuum thrombectomy (CAVT) technology designed to treat acute ischemic stroke. This device, powered by the Penumbra Engine, introduces modulated aspiration to detect, fatigue, and ingest clots at the occlusion site. Thunderbolt is currently the only CAVT device available in the U.S. for stroke treatment, marking a significant advancement in stroke care given the projected global increase in stroke mortality.
Penumbra wins FDA clearance for Thunderbolt computer-assisted vacuum thrombectomy for stroke
Penumbra announced FDA clearance for its Thunderbolt computer-assisted vacuum thrombectomy (CAVT) system for acute ischemic stroke. This system, powered by the company's Engine platform, is a first-of-its-kind for stroke treatment in the U.S., offering modulated aspiration to detect, fatigue, and ingest clots. Penumbra officials and doctors believe Thunderbolt will significantly improve stroke management and patient outcomes.
Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
Penumbra (NYSE:PEN) has received U.S. FDA clearance for its THUNDERBOLT computer assisted vacuum thrombectomy (CAVT) system for acute ischemic stroke. This system is the first and only CAVT device cleared for stroke treatment in the U.S., designed to provide faster and more complete clot removal using modulated aspiration. The device will be pre-packaged with Penumbra's RED aspiration catheters, aiming to redefine stroke care and improve patient outcomes.
Penumbra receives FDA clearance for stroke treatment device
Penumbra Inc. (NYSE:PEN) has received FDA clearance for THUNDERBOLT, a new computer-assisted vacuum thrombectomy device designed for treating acute ischemic stroke. This device, powered by the Penumbra ENGINE, uses modulated aspiration technology to enhance clot removal and is pre-packaged with various thrombectomy catheters. Despite being rated as "GREAT" financially by InvestingPro, the stock currently trades above its Fair Value, while the company also recently announced a merger with Boston Scientific Corporation.
Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
Penumbra, Inc. announced that its THUNDERBOLT™ computer assisted vacuum thrombectomy (CAVT™) platform has received FDA clearance for acute ischemic stroke treatment. This new technology introduces modulated aspiration to detect, fatigue, and ingest clots more completely, aiming to improve recovery outcomes for stroke patients. THUNDERBOLT is the first CAVT device for stroke treatment in the U.S. and represents a significant advancement in the field.
Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke – Company Announcement - FT.com
Penumbra, Inc. announced it has received U.S. FDA clearance for THUNDERBOLT, expanding its computer assisted vacuum thrombectomy (CAVT) technology to treat acute ischemic stroke. This technology, recognized as the world's first CAVT platform to deliver modulated aspiration for acute ischemic stroke, aims to enable faster and more complete clot removal. The company emphasizes that THUNDERBOLT will fundamentally change outcomes for patients suffering from stroke.
(PEN) as a Liquidity Pulse for Institutional Tactics
Quantitative analysis of Penumbra Inc. (NYSE: PEN) indicates a neutral near and mid-term outlook, with a long-term positive bias. The AI models have generated three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each tailored to different risk profiles. This analysis provides key signals, support, and resistance levels for various time horizons to guide institutional strategies.
Total operating expenses of Penumbra, Inc. – XETR:0P8
This article focuses on the "Total operating expenses" of Penumbra, Inc. (XETR:0P8), a company listed on the Deutsche Borse Xetra. It presents a simple financial data point, showing a period value, change, and percentage change. The content itself seems to be a placeholder for financial data provided by third-party services like ICE Data Services and FactSet.
Penumbra, Inc. Cash Flow – XETR:0P8
This article provides key cash flow data for Penumbra, Inc. (XETR:0P8). It highlights that the free cash flow for Q1 2026 was 63.44M EUR, and for the full year 2025, it was 148.94M EUR, with an operating cash flow of 203.20M EUR for the same year. The information is presented within the context of basic financial statements and metrics on TradingView.
Tangible book value per share of Penumbra, Inc. – XETR:0P8
This article provides financial information specifically the tangible book value per share for Penumbra, Inc. (XETR:0P8). The content appears to be a financial data snippet from a larger platform, likely TradingView, presenting the stock overview and financial metrics. The article itself does not contain detailed analysis but rather placeholders for financial data.
Penumbra, Inc. Balance Sheet – XETR:0P8
This article presents the balance sheet information for Penumbra, Inc. (XETR:0P8). As of Q1 2026, the company's total assets are 1.64 billion EUR, showing an increase of 5.66% from Q4 2025, while total liabilities rose by 8.21% to 367.52 million EUR. The data includes historical financial figures and metrics up to 2025.
PEN Technical Analysis & Stock Price Forecast
This article provides a technical analysis of Penumbra Inc. (PEN) stock, indicating a "Sell" consensus based on various indicators. It details momentum indicators like RSI and MACD, support and resistance levels, and performance relative to moving averages. The analysis suggests that while the stock is generally trading above its long-term moving averages, short-term momentum signals are negative.
Why Is Penumbra (PEN) Down 1.2% Since Last Earnings Report?
Penumbra (PEN) shares have dropped 1.2% since its last earnings report, underperforming the S&P 500. For Q1 2026, Penumbra reported an EPS of 82 cents, missing estimates by 26.1%, but revenues of $374.8 million topped estimates by 1.4%. The company maintains a Zacks Rank #3 (Hold), and analysts have not issued new estimates.
Here’s What Supports Penumbra’s (PEN) Revenue Growth and Margin Expansion
Artisan Partners' Artisan Small Cap Fund highlighted Penumbra, Inc. (NYSE:PEN) in its Q1 2026 investor letter, noting their decision to exit the investment following Boston Scientific's acquisition announcement. The fund had been building its position in Penumbra throughout 2025 due to expanding product adoption and clinical momentum, with the acquisition validating their investment thesis. Penumbra, a medical device manufacturer, saw its shares gain 23.84% over the past 52 weeks and closed at $320.63 per share on June 4, 2026.
Penumbra Class Action Reminder
Faruqi & Faruqi, LLP is reminding investors of the March 16, 2021 deadline to seek the role of lead plaintiff in a federal securities class action against Penumbra, Inc. The lawsuit alleges that Penumbra made false and misleading statements and failed to disclose design defects and safety risks of its Jet 7 Xtra Flex catheter, which led to injuries and deaths. The company's stock price declined significantly following reports and an urgent recall of the device.
Penumbra, Inc. (PEN) Stock Analysis: A Look At Growth Potential With A 14% Upside
Penumbra, Inc. (PEN) is highlighted as an intriguing investment opportunity in the medical devices industry, with a market capitalization of $12.52 billion and robust revenue growth of 15.60%. The company specializes in innovative medical devices like the Indigo System for thrombectomy, backed by strong free cash flow and a respectable return on equity. Analyst consensus suggests a generally positive outlook with an average target price indicating a potential upside of approximately 14.16%.
Penumbra Shareholder Alert
Faruqi & Faruqi, LLP is investigating potential claims against Penumbra, Inc. (NYSE:PEN) and reminds investors of the March 16, 2021 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Penumbra made false and misleading statements regarding its Jet 7 Xtra Flex catheter, which had known design defects and safety issues leading to serious injuries and deaths. The firm encourages investors who suffered losses exceeding $100,000 to contact them to discuss their legal rights.
Penumbra Shareholder Alert
Faruqi & Faruqi, LLP is investigating potential securities claims against Penumbra, Inc. (NYSE:PEN) and reminds investors of the March 16, 2021 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Penumbra made false and misleading statements about the safety of its Jet 7 Xtra Flex catheter, which was later recalled due to design defects causing injury or death. Investors who suffered losses exceeding $100,000 between August 3, 2020, and December 15, 2020, are encouraged to contact the firm.
(PEN) Risk Channels and Responsive Allocation
This article provides an AI-driven analysis for Penumbra Inc. (PEN), highlighting weak near-term sentiment despite potential long-term strength. It offers three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis indicating support and resistance levels. The analysis suggests choppy conditions due to divergent sentiment across different time horizons.
